Patricia Shi

Medical Director
Complement Biology
Complement Biology, New York Blood Center
United States of America

Scientist Haematology
Biography

Our team is interested in translational research in sickle cell disease, with the goal of helping to develop new therapies for sickle cell disease. We initiated and completed a phase I trial of intravenous gammaglobulin for pain crisis, and we are currently studying the utility of haptoglobin and/or hemopexin replacement therapy. We are also interested in studying cellular therapy aspects of sickle cell disease, such as plerixafor mobilization of hematopoietic stem cells for gene therapy and autologous cord blood characteristics.

Research Intrest

Hematology

List of Publications
Bellone M, Pham HP, Shaz BH, Shi PA (2015) Retrospective analysis of community hospital red blood cell recovery procedures: improved utilization needed for effectiveness. Transfusion 55: 1972-1979.
Choi E, Branch C, Cui MH, Yazdanbakhsh K, Mohandas N, et al. (2016) No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice. Blood Cells Mol Dis 57: 67-70.
Shi PA, Choi E, Chintagari NR, Nguyen J, Guo X, et al. (2016) Sustained treatment of sickle cell mice with haptoglobin increases HO-1 and H-ferritin expression and decreases iron deposition in the kidney without improvement in kidney function. Br J Haematol 175: 714-723.